Key result
(Neo)adjuvant chemotherapy exerted an adverse temporary effect on lipid levels, including increased triglycerides and LDL-C and decreased HDL-C, which generally restored to baseline 6 months after treatment completion.
Why the study?
Many breast cancer treatments may affect serum lipid profiles, but the patterns of change during and after chemotherapy and the effects of different regimens remained to be characterized.
Does (neo)adjuvant chemotherapy alter serum lipid profiles in women with early-stage breast cancer?
Cohort (n=805)
No
Does (neo)adjuvant chemotherapy alter serum lipid profiles in women with early-stage breast cancer?
Chemotherapy for early-stage breast cancer induces transient atherogenic lipid profile changes that resolve by 6 months post-treatment, suggesting a temporary window of increased cardiovascular risk.
May indicate temporary CV risk window during chemotherapy; leaves open need for monitoring or intervention trials in breast cancer.
Many different treatments may affect the serum lipid profiles of breast cancer patients. This study analyzed serum lipid levels at different periods during treatment to observe the changes in lipid profiles during and after chemotherapy and to compare the different effects of different chemotherapy regimens on serum lipid profiles. A total of 805 patients were included in this study. We measured the lipid profiles of patients who received surgery without chemotherapy prior to the operation and at 3, 6 and 12 months after operation. In addition, in patients who underwent chemotherapy, the lipid profiles were measured prior to chemotherapy, prior to the last cycle of chemotherapy and 6 months after chemotherapy. Lipid profile measurements included total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), homocysteine (HCY), and uric acid (UA). (Neo)Adjuvant chemotherapy exerted an adverse temporary effect on lipid levels (manifested as increased TG and LDL-C levels, and decreased HDL-C levels, particularly in the adjuvant chemotherapy group) during the chemotherapy periods. However, this influence was not sustained, as the lipid profiles levels were generally restored to baseline levels 6 months after chemotherapy completion. Different age groups showed different changes in lipid levels that were influenced by chemotherapy. The younger group (20-40 years old) showed a greater increase in TC and LDL-C levels during chemotherapy than the 41-65-year-old group. Chemotherapy exerts an adverse temporary effect, and the effects of different regimens on lipid levels are similar. Furthermore, lipid profiles in younger women may be more sensitive to chemotherapy.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2019) conducted a cohort in Early-stage breast cancer (n=805). (Neo)adjuvant chemotherapy vs. Surgery without chemotherapy was evaluated on Changes in serum lipid profiles. (Neo)adjuvant chemotherapy exerted an adverse temporary effect on lipid levels, including increased triglycerides and LDL-C and decreased HDL-C, which generally restored to baseline 6 months after treatment completion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: